Published in Tumori on July 24, 2012
Safety, efficacy, and patient acceptability of single-dose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting. Patient Prefer Adherence (2013) 0.85
Therapeutic action of 5-HT3 receptor antagonists targeting peritoneal macrophages in post-operative ileus. Br J Pharmacol (2015) 0.80
Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol (2008) 9.98
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med (2014) 4.71
Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol (2011) 3.99
Gastric cancer. Crit Rev Oncol Hematol (2009) 2.87
Epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with EGFR wild-type non-small-cell lung cancer: the never-ending story. J Clin Oncol (2013) 2.41
Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res (2005) 1.80
Dendritic cell sarcoma: an analytic overview of the literature and presentation of original five cases. Crit Rev Oncol Hematol (2007) 1.75
Oligometastatic non-small cell lung cancer: a multidisciplinary approach in the positron emission tomographic scan era. Ann Thorac Surg (2007) 1.63
Colon cancer. Crit Rev Oncol Hematol (2010) 1.62
A catalyst for change: the European cancer Patient's Bill of Rights. Oncologist (2014) 1.55
Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopasual patients. Cancer (2004) 1.48
Modulation of epidermal growth factor receptor status by chemotherapy in patients with locally advanced non-small-cell lung cancer is rare. J Clin Oncol (2004) 1.48
Capecitabine initially concomitant to radiotherapy then perioperatively administered in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys (2009) 1.46
Cancer of the prostate. Crit Rev Oncol Hematol (2005) 1.31
Extended pneumonectomy with partial resection of the left atrium, without cardiopulmonary bypass, for lung cancer. Ann Thorac Surg (2005) 1.25
Brief report: activity of imatinib in a patient with platelet-derived-growth-factor receptor positive malignant solitary fibrous tumor of the pleura. J Thorac Oncol (2008) 1.19
Participation in clinical trials as viewed by the patient: understanding cultural and emotional aspects which influence choice. Oncology (2008) 1.17
Gastric cancer. Crit Rev Oncol Hematol (2005) 1.16
Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups. Oncotarget (2014) 1.14
Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations. J Thorac Oncol (2011) 1.14
Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer. Pharmacol Rev (2003) 1.08
Treatment of collecting duct carcinoma: current status and future perspectives. Anticancer Res (2014) 1.08
The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. Eur J Cancer (2010) 1.05
Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas. Cancer Treat Rev (2010) 1.05
A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma. Clin Cancer Res (2011) 0.96
Colon cancer. Crit Rev Oncol Hematol (2004) 0.89
Palonosetron plus 1-day dexamethasone for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy: effect of established risk factors on treatment outcome in a phase III trial. J Support Oncol (2011) 0.89
Role of cMET in the development and progression of colorectal cancer. Int J Mol Sci (2013) 0.88
Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer: a systematic review and meta-analysis. Curr Drug Targets (2015) 0.87
Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors. Am J Clin Oncol (2015) 0.87
Emerging toxicities in the treatment of non-small cell lung cancer: ocular disorders. Cancer Treat Rev (2013) 0.87
Phase ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets. Oncologist (2014) 0.86
Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development. Eur J Cancer (2007) 0.85
Rectal cancer. Crit Rev Oncol Hematol (2008) 0.84
ΔNp63 (p40) distribution inside lung cancer: a driver biomarker approach to tumor characterization. Int J Surg Pathol (2013) 0.82
¹⁸F-FLT PET/CT as an imaging tool for early prediction of pathological response in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy: a pilot study. Eur J Nucl Med Mol Imaging (2015) 0.82
Targeted therapies in advanced renal cell carcinoma: the role of metastatic sites as a prognostic factor. Future Oncol (2014) 0.82
Experience with sorafenib in the treatment of advanced renal cell carcinoma. Ther Adv Urol (2012) 0.82
Continuing single-agent bevacizumab as maintenance therapy after induction XELOX (or FOLFOX) plus bevacizumab in first-line treatment of metastatic colorectal cancer. Oncologist (2012) 0.82
Feasibility study of biweekly capecitabine, oxaliplatin, and irinotecan in patients with untreated advanced gastric cancer. Tumori (2009) 0.82
Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases. Med Oncol (2015) 0.81
Factor v leiden mutation in patients with breast cancer with a central venous catheter: risk of deep vein thrombosis. Support Cancer Ther (2006) 0.81
Respiratory function changes after chemotherapy: an additional risk for postoperative respiratory complications? Ann Thorac Surg (2004) 0.81
Safety, tolerability and biological effects of long-term metronomic administration of non-cytotoxic anti-angiogenic agents. Oncology (2010) 0.80
Bax expression is predictive of favorable clinical outcome in chemonaive advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimen. Transl Oncol (2012) 0.80
Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trials. Br J Clin Pharmacol (2014) 0.80
Absence of epidermal growth factor receptor gene mutations in patients with hormone refractory prostate cancer not responding to gefitinib. Prostate (2007) 0.79
Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer. Target Oncol (2011) 0.79
Everolimus in advanced solid tumors: when to start, early or late? Tumori (2014) 0.79
Role of BAX for outcome prediction in gastrointestinal malignancies. Med Oncol (2013) 0.78
Palonosetron plus dexamethasone in highly emetogenic chemotherapy: pooled data from two Phase III trials. Future Oncol (2013) 0.78
Biological insights into BRAF(V600) mutations in melanoma patient: Not mere therapeutic targets. Oncoimmunology (2013) 0.78
Is a dexamethasone-sparing strategy capable of preventing acute and delayed emesis caused by combined doxorubicin and paclitaxel for breast cancer? Analysis of a phase II trial. Oncology (2013) 0.78
Adjuvant chemotherapy in new stage II pN0 non-small cell lung cancer: a new issue for a case-by-case decision making process. J Thorac Oncol (2010) 0.78
Safety profile and treatment response of everolimus in different solid tumors: an observational study. Future Oncol (2014) 0.78
Time from nephrectomy as a prognostic factor in metastatic renal cell carcinoma patients receiving targeted therapies: overall results from a large cohort of patients. Oncology (2014) 0.78
Is the standardized uptake value of FDG-PET/CT predictive of pathological complete response in locally advanced rectal cancer treated with capecitabine-based neoadjuvant chemoradiation? Oncology (2013) 0.78
A proper schedule of weekly paclitaxel and gemcitabine combination is highly active and very well tolerated in NSCLC patients. Lung Cancer (2006) 0.77
Targeted therapies and survival: what we can learn from studies in advanced renal cell carcinoma. Oncology (2012) 0.77
Simplified FOLFIRI in pre-treated patients with metastatic gastric cancer. Cancer Chemother Pharmacol (2008) 0.77
TP53 mutations in advanced colorectal cancer: the dark side of the moon. Oncology (2014) 0.77
Sequential Tyrosine Kinase Inhibitors (TKIs) in metastatic renal cell carcinoma: results from a large cohort of patients. Anticancer Res (2014) 0.77
T-cell activation and maturation at tumor site associated with objective response to ipilimumab in metastatic melanoma. J Clin Oncol (2011) 0.76
Real-world study of everolimus in advanced progressive neuroendocrine tumors. Oncologist (2015) 0.76
Re: Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. J Natl Cancer Inst (2007) 0.76
New perspectives in advanced genitourinary malignancies. Tumori (2012) 0.76
Re: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst (2005) 0.75
Prophylaxis for venous thromboembolism in cancer patients with a central vein catheter: new tones for an old song. J Clin Oncol (2005) 0.75
Preoperative chemotherapy in non-small-cell lung cancer: nothing new in N2 disease. J Clin Oncol (2002) 0.75
Tackling off-label use of anticancer drugs. J Clin Oncol (2012) 0.75
Target-treatment and patients' selection: can we still neglect the timing of tissue collection? J Clin Oncol (2005) 0.75
Drug-induced prolongation of the QT interval. N Engl J Med (2004) 0.75
Lecture: management of chemotherapy-induced febrile neutropenia; guidelines and colony stimulating factors. Neurol Sci (2011) 0.75
Health-related quality of life in patients with hormone refractory prostate cancer receiving gefitinib. Urol Int (2009) 0.75
Three-times-daily radiotherapy with induction chemotherapy in locally advanced non-small cell lung cancer. Feasibility and toxicity study. Strahlenther Onkol (2005) 0.75
Gastrointestinal stromal tumors: should they be treated with the same systemic chemotherapy as other soft tissue sarcomas? Oncology (2003) 0.75
Optimization of the schedule of gemcitabine-cisplatin combination as induction regimen for patients with biopsy-proven stage IIIa N2 - stage IIIb non-small-cell lung cancer: a prospective phase-II study. Bull Cancer (2004) 0.75
Does immunohistochemistry affect response to therapy and survival of inoperable non-small cell lung carcinoma patients? A survey of 145 stage III-IV consecutive cases. Int J Surg Pathol (2013) 0.75
Fatal case of hepatic portal venous gas following palliative stenting and chemotherapy for occlusive advanced colorectal cancer. Int J Colorectal Dis (2014) 0.75
Preoperative Capecitabine, Oxaliplatin, and Irinotecan in Resectable Gastric or Gastroesophageal Junction Cancer: Pathological Response as Primary Endpoint and FDG-PET Predictions. Oncology (2017) 0.75
Small-Cell Lung Cancer: Clinical Management and Unmet Needs New Perspectives for an Old Problem. Curr Drug Targets (2017) 0.75
Erlotinib combined with cyclosporine in a liver-transplant recipient with epidermal growth factor receptor-mutated non-small cell lung cancer. J Thorac Oncol (2009) 0.75
Features and prognostic factors of large node-negative non-small-cell lung cancers shifted to stage II. J Thorac Oncol (2012) 0.75
Patient approach in advanced/metastatic renal cell carcinoma: focus on the elderly population and treatment-related toxicity. Future Oncol (2013) 0.75
Highlights from the ASCO Genitourinary Symposium 2014: focus on renal and prostate cancer. Expert Rev Anticancer Ther (2014) 0.75
A 15-min premedication for 1-h paclitaxel infusion: optimizing patients' care. Lung Cancer (2007) 0.75
"Systemic strategy at the patient's service": a congress report on supportive care in oncology. Tumori (2017) 0.75